Biosynthetic production of psilocybin and related intermediates in recombinant organisms

US11441164B2 · kind B2 · utility

Assignee

• CB Therapeutics, Inc. · US

Inventors

• Jacob Michael Vogan · Oakland, US
• Laura Flatauer Peiffer · Carlsbad, US
• James Wade · San Diego, US
• Tyrone Jacob Yacoub · Murrieta, US
• Kirsten Tang · Carlsbad, US
• Rachel Nadine Burnett · San Diego, US

Key dates

• Filing date: Nov 16, 2020
• Grant date: Sep 13, 2022
• Expiry date: Nov 16, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Y205/01054
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The systems and methods herein include engineering a host to produce psilocybin using engineered enzymes, genetic changes, and exogenous psilocybin precursor addition (e.g., addition of L-tryptophan to a growing culture of a psilocybin producing recombinant host strain). The process occurs in genetically engineered host cell(s) that can produce psilocybin.